News

Reader based multiplex lateral flow assays are opening new opportunities for biomarker signatures, structured data capture and algorithmic interpretation. This article explores how candidate markers can be assessed, translated into lateral flow and developed into reliable diagnostic systems with the reader, software, manufacture and regulatory pathway considered from the start.

Rapid antibody screening can help identify stronger antibody candidates earlier in immunoassay development. Fleet supports antibody screening across lateral flow, ELISA, Gyrolab™ and other assay formats, with small-volume screening approaches and in-house bioconjugation capability to support better assay decisions.

Sustainability in lateral flow testing is broader than material substitution. This article explores how material design, reagent strategy, manufacturing yield, performance testing, supply chain choices and at-source testing can reduce waste across the full lateral flow test lifecycle.

Fleet Bioprocessing will be attending Sensors for Health 2026 at Swansea University on 29 April. The event brings together researchers and industry working in health related sensor development, diagnostics and translation.

This guide to lateral flow assay development explains how to improve assay sensitivity and reproducibility through antibody screening, membrane selection, conjugate optimisation, strip design and process control.

Antibody selection is one of the most influential decisions made during early Lateral Flow Assay (LFA) development. Whether antibodies are sourced commercially or developed as part of a broader LFA development service, the choices made at this stage directly affect assay sensitivity, specificity, reproducibility and long-term manufacturability. Applying a structured, risk based approach to antibody evaluation can significantly reduce technical and commercial challenges later

Lateral Flow Assays (LFAs) may look simple, but successful development is far from straightforward. Behind reliable, consistent performance lies careful control of multiple interacting variables that can otherwise introduce hidden risk. Too often, development challenges surface late, when changes are costly, timelines slip and verification efforts fail. The difference between a smooth path to market and repeated re-design frequently comes down to early technical decisions and